Evidence map›Paper›PMID 31112940›Full record

Trial reportActa haematologica2019

Proteomic Profiling of Signaling Networks Modulated by G-CSF/Plerixafor/Busulfan-Fludarabine Conditioning in Acute Myeloid Leukemia Patients in Remission or with Active Disease prior to Allogeneic Stem Cell Transplantation.

Zhihong Zeng, Wenbin Liu, Christopher B Benton, Sergej Konoplev, Hongbo Lu, Rui-Yu Wang, Julianne Chen, Elizabeth Shpall, Keith A Baggerly, Richard Champlin and 1 more

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Acta haematologica, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Targeting CXCR4 in AML and ALL.Frontiers in oncology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Zhihong ZengDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Wenbin LiuDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Christopher B BentonDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Sergej KonoplevDepartment of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Hongbo LuDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Rui-Yu WangDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Julianne ChenDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Elizabeth ShpallDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Keith A BaggerlyDepartment of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Richard ChamplinDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Marina KonoplevaDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mkonople@mdanderson.org.
The University of Texas MD Anderson Cancer Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8M
Targeting the leukemia microenvironment by CXCR4 inhibition in stem cell transplaR21CA137637 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KONOPLEVA, MARINA Y · 2009 to 2010
$678k
NCI NIH HHS P30 CA016672NCI NIH HHS R21 CA137637
6 · The paper itself

Abstract

To characterize intracellular signaling in peripheral blood (PB) cells of acute myeloid leukemia (AML) patients undergoing pretransplant conditioning with CXCR4 inhibitor plerixafor, granulocyte colony-stimulating factor (G-CSF), and busulfan plus fludarabine (Bu+Flu) chemotherapy, we profiled 153 proteins in 33 functional groups using reverse phase protein array. CXCR4 inhibition mobilized AML progenitors and clonal AML cells, and this was associated with molecular markers of cell cycle progression. G-CSF/plerixafor and G-CSF/plerixafor/Bu+Flu modulated distinct signaling networks in AML blasts of patients undergoing conditioning with active disease compared to nonleukemic PB cells of patients in remission. We identified AML-specific proteins that remained aberrantly expressed after chemotherapy, representing putative chemoresistance markers in AML.

Indexed as

Hematopoietic Stem Cell MobilizationLeukemia, Myeloid, AcuteProteomicsSignal TransductionTransplantation ConditioningAdultAllograftsBenzylaminesBusulfanCyclamsFemaleGranulocyte Colony-Stimulating FactorHeterocyclic CompoundsHumansMaleMiddle AgedBenzylaminesBusulfanCyclamsfludarabineGranulocyte Colony-Stimulating FactorHeterocyclic CompoundsNeoplasm ProteinsplerixaforVidarabineAcute myeloid leukemiaAllogeneic stem cell transplantationCXCR4PlerixaforProteomic profiling of signaling

Identifiers

PMID31112940
PMCPMC6792289
OpenAlexW2945631467

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.